ClinicalTrials.gg
RecruitingNCT05232240BPV-NhICVDUpdated Mar 14, 2022

Blood Pressure Variability in Non-hypertensive Patients With Ischemic Cerebrovascular Disease

An observational study in Ischemic Cerebrovascular Disease and Blood Pressure Variability, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-14.

Sponsored by Xuanwu Hospital, Beijing · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing — 30 open to participants now, 31 under way, 2 of them phase 3. Ischemic Stroke · Xuanwu Hospital, Beijing.

Planned enrollment
13th of 24
300 · median 350
Started
2022
with 3 others
Observational
24 of 52
15 open now
Primary completion
2027-02
later than 12 of 30 live
Registered
13th of 52
by date

Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, this one is the 13th largest by planned enrollment of the 24 observational ones that give a count, is one of 4 that started in 2022, is one of 24 observational ones, reaches primary completion later than 12 of the 30 other live ones, and was the 13th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

30 of the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

This study is a single-center prospective cohort of patients with ischemic cerebrovascular disease (ICVD) who have not met the diagnostic criteria for hypertension. Ambulatory 24-hour blood pressure monitoring (ABPM) will be performed at baseline and one year after the enrollment. The primary purpose of the study is to delineate the relationship of blood pressure variability (BPV) with the risk of composite vascular events in non-hypertensive patients with ICVD. The factors related to BPV, as well as the potential modulators of the associations between BPV and vascular risk, will be further explored among these patients.

Read the detailed description

Hypertension is one of the most important risk factors of ischemic cerebrovascular disease (ICVD), while various blood pressure variability (BPV) indices are immerging as novel prognostic indicators independent of the blood pressure level. However, the BPV profiles without hypertension have not been specifically observed. Considering the great importance of blood pressure management in ICVD, more research is needed to clarify whether and how BPV will increase the vascular risk in non-hypertensive patients with ICVD. This prospective cohort study will be helpful to invoke an early management of blood pressure in patients with ICVD before the clinical establishment of hypertension.

All eligible non-hypertensive patients hospitalized for ICVD will be consecutively enrolled in this cohort. Blood pressure measurements are obtained with ambulatory 24-hour blood pressure monitoring (ABPM) every 20 minutes during day-time (6:00-22:00) and every 30 minutes during night-time (22:00-6:00) at baseline and one year after the enrollment. The clinical, imaging and laboratory information will be collected at baseline. During an estimated 3-year follow-up, the vessel-related diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports and investigators' regular telephone visits.

03

Conditions studied

  • Ischemic Cerebrovascular Disease
  • Blood Pressure Variability

Keywords

  • ischemic stroke
  • transient ischemic attack
  • non-hypertensive
  • blood pressure variability
  • vascular risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients are diagnosed as ischemic cerebrovascular disease (ICVD) and less than 90 days after the onset of ischemic stroke or transient ischemic attack. The patients have no definite diagnosis of hypertension, and are not under anti-hypertension treatment. The blood pressure measured 5\~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥ 2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed as ischemic stroke or (TIA), with confirmation of computed tomography or magnetic resonance imaging.
  2. Less than 90 days after onset of ischemic stroke or TIA symptoms.
  3. The blood pressure measured 5\~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement).
  4. Consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. A definite diagnosis of hypertension.
  2. Under anti-hypertension treatment.
  3. Worsening neurological conditions.
  4. With a National Institute of Health Stroke Scale score more than 5 points.
  5. Intracranial hemorrhage.
  6. Autonomic failure.
  7. With malignant tumors or poor organ functions or hematologic diseases, whose estimated is less than 3 years.
  8. With to ambulatory 24-hour blood pressure monitoring or fail to finish the examination at baseline.
  9. Mental disease.
  10. Pregnant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Non-hypertensive patients with Ischemic Cerebrovascular Disease

    The patients are diagnosed as ischemic cerebrovascular disease (ICVD) and less than 90 days after the onset of ischemic stroke or transient ischemic attack. The patients have no definite diagnosis of hypertension, and are not under anti-hypertension treatment. The blood pressure measured 5\~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥ 2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement).

    Diagnostic Test: blood pressure variability measured by ambulatory 24-hour blood pressure monitoring

Interventions

  • Diagnostic testblood pressure variability measured by ambulatory 24-hour blood pressure monitoring

    The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.

06

What researchers measure

Primary outcomes

  1. 3-year risk of Major Adverse Cardiovascular Event

    the time of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina

    Time frame: 3 years

Secondary outcomes

  1. 90-day Functional Outcome

    percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled

    Time frame: 90 days

  2. 1-year rate of Major Adverse Cardiovascular Event

    the rate of cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina

    Time frame: 1 year

  3. 1-year rate of Ischemic Stroke

    the rate of fatal and nonfatal ischemic stroke

    Time frame: 1 year

  4. 1-year rate of Acute Coronary Syndrome

    the rate of first documented fatal and nonfatal myocardial infarction and unstable angina

    Time frame: 1 year

  5. 1-year rate of Cardiovascular Mortality

    the rate of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death

    Time frame: 1 year

  6. 3-year risk of Ischemic Stroke

    the time of first documented fatal or nonfatal ischemic stroke

    Time frame: 3 years

  7. 3-year risk of Acute Coronary Syndrome

    the time of first documented fatal or nonfatal myocardial infarction or unstable angina

    Time frame: 3 years

  8. 3-year risk of Cardiovascular Mortality

    the time of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 60 months is close to that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2022
First posted
Feb 9, 2022
StartActual
Feb 14, 2022
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2028
Last update
Mar 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05232240
Responsible party
Xin Ma (Principal investigator, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Feb 9, 2022
Start date
Feb 14, 2022
Primary completion
Feb 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Mar 14, 2022

Study contacts

Xin Ma, MD, PhD
Contact
maxin118@hotmail.com
13501390691

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion